Sexual dysfunction includes desire, arousal, orgasmic and sex pain
disorders (dyspareunia and vaginismus). Primary care physicians must
assume a proactive role in the diagnosis and treatment of these
disorders. Long-term medical diseases, minor ailments, medications and
psychosocial difficulties, including prior physical or sexual abuse, are
etiologic factors. Gynecologic maladies and cancers (including breast
cancer) are also frequent sources of sexual dysfunction. Patient
education and reassurance, with early diagnosis and intervention, are
essential for effective treatment. Patient history and physical
examination techniques, normal sexual responses and the factors that
influence these responses, and the application of medical and
gynecologic treatments to sexual issues are discussed. Basic treatment
strategies, which may be successfully provided by primary care
physicians for most sexual dysfunctions, are outlined. Referral can be
reserved for patients who do not respond to therapy.
Sexuality is a complex process, coordinated by the neurologic, vascular and endocrine systems. Individually, sexuality incorporates family, societal and religious
beliefs, and is altered with aging, health status and personal
experience. In addition, sexual activity incorporates interpersonal
relationships, each partner bringing unique attitudes, needs and
responses into the coupling. A breakdown in any of these areas may lead
to sexual dysfunction.Primary care physicians, skilled in the treatment of medical and psychologic disorders, often feel unqualified to treat patients with sexual dysfunction. However, with an understanding of sexual functioning and application of general medical and gynecologic treatments to sexual issues, sexual dysfunction may be effectively approached with the same skills. The latter includes obtaining a complete patient history, conducting a physical examination, application of basic treatment strategies, providing patient education and reassurance, and recommending appropriate referral when indicated.
Diagnosis
Female sexual dysfunction can be subdivided into desire, arousal, orgasmic and sexual pain disorders. Sexual pain disorders include dyspareunia and vaginismus.Estimates of the number of women who have sexual dysfunction range from 19 to 50 percent in “normal” outpatient populations and increase to 68 to 75 percent when sexual dissatisfaction or problems (not dysfunctional in nature) are included. Yet, one review of physicians' chart notes revealed a recorded sexual problem in only 2 percent. In another review, physician inquiry of patients in a gynecologic office setting about sexual problems increased reported complaints about sexual dysfunction sixfold. This discrepancy demonstrates a need for physician education in this area.
The diagnosis of female sexual dysfunction requires the physician to obtain a detailed patient history that defines the dysfunction, identifies causative or confounding medical or gynecologic conditions, and elicits psychosocial information.Preappointment questionnaires or appointments at which only the history is taken allow patient-physician communication to be unhindered by time constraints or patient fears of an upcoming physical examination.
Establishment of the patient's sexual orientation is necessary for appropriate evaluation and management. Nonjudgmental, direct questions best achieve this goal. Because gender identity conflicts are often a cause of sexual dysfunction, the mode and type of questions asked by physicians should create an environment where patients may openly express their concerns. Specialized counseling is important for these patients.
The sexual dysfunction should be defined in terms of onset and duration and situational versus global effect. A situational dysfunction occurs with a specific partner, in a certain setting or in a definable circumstance.
The presence of more than one dysfunction should be ascertained, because considerable interdependence may exist. For example, a patient complaining about decreased desire might have a primary orgasmic disorder from insufficient stimulation, with decreased desire developing secondarily as a result of unsatisfying sexual encounters (Thus, treating the orgasmic disorder would indirectly enhance desire; whereas, treating a desire disorder would be unsuccessful and perhaps add to patient frustration and perpetuate the cycle of dysfunction.
FIGURE 1.
Cycle
of sexual dysfunction. Example showing how a patient can enter the
cycle of sexual dysfunction in one area (i.e., decreased orgasm) and
proceed to another area (i.e., decreased desire) so that the presenting
complaint may not represent the problem that actually requires
evaluation and treatment.
Adapted with permission from Phillips NA. The clinical evaluation of dyspareunia. Int J Impot Res 1998;10(suppl 2):S117–20.
Medical conditions are a frequent source of direct or indirect sexual difficulties. Vascular disease associated with diabetes might preclude adequate arousal; cardiovascular disease may inhibit intercourse secondary to dyspnea Arthritis or urinary incontinence may cause discomfort or embarrassment, leading to dysfunction or decreased sexual activity.Aggressive treatment of long-term disease and minor ailments, with attention to their sexual implications, will help enhance sexuality.
Medical Causes of Female Sexual Dysfunction
Prescription and over-the-counter medications, illicit drugs and alcohol abuse contribute to sexual dysfunction
Medication changes, drug discontinuation, or dosage or schedule
alterations may provide relief. Cigarette smoking, known to cause
erectile dysfunction in men, may have a similar negative effect on
arousal in women.
The
rightsholder did not grant rights to reproduce this item in electronic
media. For the missing item, see the original print version of this
publication.
Medications and Female Sexual Dysfunction
Medications that cause disorders of desire
| |
Psychoactive medications
| |
Antipsychotics
| |
Barbiturates
| |
Benzodiazepines
| |
Selective serotonin reuptake inhibitors
| |
Lithium
| |
Tricyclic antidepressants
| |
Cardiovascular and antihypertensive medications
| |
Antilipid medications
| |
Beta blockers
| |
Clonidine (Catapres)
| |
Digoxin
| |
Spironolactone (Aldactone)
| |
Hormonal preparations
| |
Danazol (Danocrine)
| |
GnRh agonists (e.g., Lupron, Synarel)
| |
Oral contraceptives
| |
Other
| |
Histamine H2-receptor blockers and promotility agents
| |
Indomethacin (Indocin)
| |
Ketoconazole (Nizoral)
| |
Phenytoin sodium (Dilantin)
| |
Medications that cause disorders of arousal
| |
Anticholinergics
| |
Antihistamines
| |
Antihypertensives
| |
Psychoactive medications
| |
Benzodiazepines
| |
Selective serotonin reuptake inhibitors
| |
Monoamine oxidase inhibitors
| |
Tricyclic antidepressants
| |
Medications that cause orgasmic dysfunction
| |
Methyldopa (Aldomet)
| |
Amphetamines and related anorexic drugs
| |
Antipsychotics
| |
Benzodiazepines
| |
Selective serotonin reuptake inhibitors
| |
Narcotics
| |
Trazadone (Desyrel)
| |
Tricyclic antidepressants*
| |
*—Also associated with painful orgasm
Adapted with permission from Drugs that cause sexual dysfunction: an update. Med Lett Drugs Ther 1992;34:73–8.
Gynecologic Causes of Female Sexual Dysfunction and Method of Gynecologic Examination
| Examination | Condition |
|---|---|
External genitalia
| |
Assess muscle tone
|
Vaginismus
|
Assess skin color and texture
|
Vulvar dystrophy, dermatitis
|
Assess skin turgor and thickness
|
Atrophy
|
Assess pubic hair amount and distribution
|
Atrophy
|
Expose clitoris
|
Clitoral adhesions
|
Assess for ulcers
|
Herpes simplex virus
|
Perform cotton swab test of vestibule
|
Vulvar vestibulitis
|
Palpate Bartholin glands
|
Bartholinitis
|
Assess posterior forchette and hymenal ring
|
Episiotomy scars, strictures
|
Monomanual
|
|
Palpate rectovaginal surface
|
Rectal disease
|
Palpate levator ani
|
Levator ani myalgia, vaginismus
|
Palpate bladder/urethra
|
Urethritis, interstitial cystitis, urinary tract infection
|
Assess for cervical motion tenderness
|
Infection, peritonitis
|
Assess vaginal depth
|
Postoperative changes, postradiation changes, stricture
|
Bimanual
|
|
Palpate uterus
|
Retrogression, fibroids, endometritis
|
Palpate adnexa
|
Masses, cysts, endometriosis, tenderness
|
Perform rectovaginal examination
|
Rule out endometriosis
|
Obtain guaiac test
|
Bowel disease
|
Speculum
|
|
Evaluate discharge, pH
|
Vaginitis, atrophy
|
Evaluate vaginal mucosa
|
Atrophy
|
Perform Papanicolaou smear
|
Human papillomavirus infection, cancer
|
Assess for prolapse
|
Cystocele, rectocele, uterine prolapse
|
Adapted with permission from Phillips NA. The clinical evaluation of dyspareunia. Int J Impot Res 1998;(suppl 2):S117–20.
Gynecologic changes related to a woman's reproductive life (e.g., puberty, pregnancy, the postpartum period and menopause) present unique problems and potential obstacles to sexuality. Puberty may lead to concerns regarding sexual identity. Pregnancy and the postpartum period are often associated with a decrease in sexual activity, desire and satisfaction, which may be prolonged with lactation.
The hypoestrogenic state of menopause may cause significant physical changes and alterations in mood or a diminished sense of well-being, which have been found to have a significant, negative impact on sexuality. A decline in desire, arousal and frequency of intercourse and an increase in dyspareunia have been associated with menopause, although these findings are not universal.
Physiologic Changes of Menopause
Skin
|
Decreased activity of sweat and sebaceous glands, decreased tactile stimulation
|
Breasts
|
Decreased fat content, decreased breast swelling and nipple erectile response with sexual arousal
|
Vagina
|
Shortening
and loss of elasticity of vaginal barrel, diminished physiologic
secretions, rise in vaginal pH from 3.5 to 4.5 to greater than 5,
thinning of epithelial layers
|
Internal reproductive organs
|
Ovaries
and fallopian tubes diminish in size, ovarian follicles undergo
atresia, ovarian stroma becomes fibrotic, uterine body weight decreases
30 to 50 percent, cervix atrophies and decreases mucous production
|
Bladder
|
Urethra and bladder trigone atrophy
|
Reproduced
with permission from Phillips NA, Rosen RC. Menopause and sexuality.
In: Lobo RA, ed. Treatment of the postmenopausal woman. 2d ed.
Phildelphia: Lippincott Williams and Wilkins, 1999:437–43.
Psychosocial Factors of Female Sexual Dysfunction
Intrapersonal conflicts
|
Religious taboos, social restrictions, sexual identity conflicts, guilt (i.e., widow with new partner)
|
Historical factors
|
Past or current abuse (sexual, verbal, physical), rape, sexual inexperience
|
Interpersonal conflicts
|
Relationship
conflicts; extra-marital affairs; current physical, verbal or sexual
abuse; sexual libido; desire or practices different from partner; poor
sexual communication
|
Life stressors
|
Financial, family or job problems, family illness or death, depression
|
PHYSICAL EXAMINATION
Each patient should
undergo a thorough examination, with the gynecologic examination
individually guided by and tailored to patient comfort. The goal of the
examination is detection of disease; however, the examination also
provides an opportunity to educate the patient about normal anatomy and
sexual function, and to reproduce and localize pain encountered during
sexual activity.A routine examination seeks signs of general medical conditions. The gynecologic examination is comprehensive beginning with inspection of the external genitalia, including a cotton swab test if indicated (gently touching the vestibule of the vagina with a cotton swab will elicit moderate to severe pain in patients with vulvar vestibulitis). For patients with dyspareunia, a “mono-manual” examination should follow, with one or two fingers in the vagina (proceeding from posterior to anterior), and the other hand held away from the abdomen so as not to confuse the source of discomfort Bimanual and rectovaginal examinations are then performed. The timing of the speculum examination is guided by patient symptoms. In patients with deep dyspareunia, the speculum examination should follow the bimanual examination because localization of pain is crucial in these patients. In patients in whom vaginitis, cervical cancer or a sexually transmitted disease is suspected, cultures and vaginal samples should be obtained first.
Laboratory testing should be guided by patient symptoms and examination findings. No specific tests are universally recommended for patients with sexual dysfunction. Attention to routine screening tests must not be overlooked.
General Treatment Guidelines
Following the patient history and physical examination, a suspected etiology may be treated.If no etiology is discovered, basic treatment strategies are applied The patient's (and partner's) personal tastes and comfort must be considered. Physicians should respect a patient's choice to decline treatment, because studies show that sexual activity is not correlated with overall sexual satisfaction or intimacy in all persons. In general, treatments are similar despite sexual orientations.
Basic Treatment Strategies for Female Sexual Dysfunction
Provide education
|
Provide
information and education (e.g., about normal anatomy, sexual function,
normal changes of aging, pregnancy, menopause). Provide booklets,
encourage reading; discuss sexual issues when a medical condition is
diagnosed, a new medication is started, and during pre- and
postoperative periods; give permission for sexual experimentation.
|
Enhance stimulation and eliminate routine
|
Encourage
use of erotic materials (videos, books); suggest masturbation to
maximize familiarity with pleasurable sensations; encourage
communication during sexual activity; recommend use of vibrators*;
discuss varying positions, times of day or places; suggest making a
“date” for sexual activity.
|
Provide distraction techniques†
|
Encourage
erotic or nonerotic fantasy; recommend pelvic muscle contraction and
relaxation (similar to Kegel exercise) exercises with intercourse;
recommend use of background music, videos or television.
|
Encourage noncoital behaviors‡
|
Recommend
sensual massage, sensate-focus exercises (sensual massage with no
involvement of sexual areas, where one partner provides the massage and
the receiving partner provides feedback as to what feels good; aimed to
promote comfort and communication between partners); oral or noncoital
stimulation, with or without orgasm.
|
Minimize dyspareunia
|
Superficial: female astride for control of penetration, topical lidocaine, warm baths before intercourse, biofeedback.
|
Vaginal: same as for superficial dyspareunia but with the addition of lubricants.
|
Deep:
position changes so that force is away from pain and deep thrusts are
minimized, nonsteroidal anti-inflammatory drugs before intercourse.
|
note: For a review, see Striar S, Bartlik B. Stimulation of the libido: the use of erotica in sex therapy. Psych Annals 1999;29:60–2.
—Provide information for obtaining one discreetly.
—Helpful in eliminating anxiety, increasing relaxation and diminishing spectatoring.
—Also helpful if partner has erectile dysfunction.
DISORDERS OF DESIRE
Women with disorders of
desire are difficult to treat. Occasionally, decreased desire in
patients is secondary to boredom with sexual routines. Suggesting
changes in positions or venues, or the addition of erotic materials is
helpful.Disorders of desire in premenopausal patients may be secondary to lifestyle factors (e.g., careers, children), medications or another sexual dysfunction (e.g., pain or orgasmic disorder). No medical treatment is available specific to patients with disorders of desire. If no underlying medical or hormonal etiology is discovered, individual or couple counseling may be helpful.
In peri- and postmenopausal women, the relationship between hormones and sexuality is unclear. Nonetheless, estrogen replacement therapy has been shown to correlate positively with sexual activity, enjoyment and fantasies—the latter thought to represent desire. The mechanism of estrogen's effect on desire is indirect and occurs through improvement in urogenital atrophy, vasomotor symptoms and menopausal mood disorders (i.e., depression). This relationship helps predict which patients are likely to respond to estrogen replacement therapy (i.e., those with symptoms of hypoestrogenism) and may explain why some studies do not show estrogen-mediated improvement in sexual functioning.
The role of progesterone therapy, which is necessary in estrogen-treated patients with an intact uterus, has not been widely studied in terms of sexuality, but one study suggests that it exhibits a negative impact by dampening mood and decreasing available androgens. The addition of estrogen for several weeks before progesterone therapy is initiated, or taking into account monthly symptom calendars, will help determine each hormone's influence and guide dosage and schedule adjustments.
Testosterone appears to have a direct role in sexual desire. However, because studies evaluate mostly testosterone-deficient, oophorectomized women or women who develop supraphysiologic levels secondary to testosterone treatment, clinical applications are limited. No guidelines for testosterone replacement therapy for women with disorders of desire and no consensus of “normal” or “therapeutic” levels of testosterone therapy exist. Many physicians are concerned about the lack of safety data on the role of testosterone in breast cancer and on hepatic side effects; however, hepatocellular damage or carcinoma is rare at prescribed dosages, and the development of breast cancer has not been reported clinically.
The side effects of testosterone, which occur in 5 to 35 percent of patients, include lower levels of high-density lipoprotein, acne, hirsutism, clitorimegaly and voice deepening. However, these side effects on lipoprotein levels are rarely significant if estrogen and testosterone are coadministered; moreover, most other side effects are reversible with discontinuation of testosterone or a dosage adjustment.
A role for testosterone treatment exists in selected patients . Coadministration with estrogen therapy should be provided to prevent deleterious effects on lipoprotein levels. Before initiating testosterone treatment, physicians should discuss the potential and theoretic risks, and individual risk and benefit assessments with the patient. In general, patients with current or previous breast cancer, uncontrolled hyperlipidemia, liver disease, acne or hirsutism should not receive testosterone therapy.
Testosterone Therapy for Treatment of Disorders of Desire
Screening
|
Baseline
testosterone levels† (free and total), baseline lipid profile, baseline
liver enzyme levels, mammography, Papanicolaou smear
|
Initiate therapy‡
|
Combination product (Estratest or Estratest hs)
|
Methyltestosterone (Android), 1.25 to 2.5 mg daily
|
Micronized oral testosterone, 5 mg twice daily
|
Testosterone proprionate 2 percent in petroleum applied daily to every other day
|
Testosterone injectables/pellets
|
Reevaluation at three to four months
|
Repeat testosterone levels, lipid profile, liver enzyme levels
|
Monitor symptoms, side effects
|
Continued therapy
|
Taper to lowest effective dosage
|
Monitor lipid levels, liver enzyme levels once or twice yearly
|
Routine Papanicolaou smear and mammography schedules
|
—These
are recommendations; no evidence-based protocols are available on
testosterone therapy for the treatment of women with desire disorders.
—Many authors recommend that total levels remain in “normal” range for pre-menopausal women.
—None of these medications are labeled by the U.S. Food and Drug Administration for treatment of desire disorders.
—Alternate
daily combined with estrogen-only pill, take testosterone pill every
other day, 5 days a week, etc. (not shown in studies to be safer or have
fewer side effects).
AROUSAL DISORDERS
Current treatment of
patients with arousal disorders is limited to the use of commercial
lubricants, although vitamin E and mineral oils are also options.
Arousal disorders may be secondary to inadequate stimulation, especially
in older women who require more stimulation to reach a level of arousal
that was more easily attained at a younger age. Encouraging adequate
foreplay or the use of vibrators to increase stimulation may be helpful.
Taking a warm bath before intercourse may also increase arousal.
Anxiety may inhibit arousal, and strategies to alleviate anxiety by
employing distraction techniques are helpful.Urogenital atrophy is the most common cause of arousal disorders in postmenopausal women, and estrogen replacement, when appropriate, is usually effective therapy. However, women taking systemic estrogens occasionally require supplementation with local therapy. Long-term use of estrogen-containing vaginal creams is considered an unopposed-estrogen treatment in women with an intact uterus, requiring progesterone opposition. An oral progesterone such as medroxyprogesterone 5 mg daily for 10 days every one to three months (or equivalent) may be used initially, with frequency or dosage increased if withdrawal bleeding occurs. Estring (an estradiol-containing vaginal ring) has little systemic absorption and does not require the addition of progesterone. Patients who are uncomfortable wearing the ring during the day often achieve relief with night use only.
Premenopausal women with arousal disorders, women who do not respond to estrogen therapy and women who are unable or unwilling to take estrogen represent difficult patient groups because few treatment options are available.
Investigators recognize that small-vessel atherosclerotic disease of the vagina and clitoris may contribute to arousal disorders and are exploring vasoactive medications as treatment. Small studies have been conducted with favorable results, but larger studies are needed. Currently, treatment of arousal disorder in women who are taking these medications, including sildenafil (Viagra), is not recommended, although anecdotal success has been reported.
ORGASMIC DISORDERS
Anorgasmia is quite
responsive to therapy. This condition is caused by sexual inexperience
or the lack of sufficient stimulation and is common in women who have
never experienced orgasm. Orgasmic disorders may also be psychologic
(“involuntary inhibition” of the orgasmic reflex) or caused by
medications or chronic disease.Treatment relies on maximizing stimulation and minimizing inhibition. Stimulation may include masturbation with prolonged stimulation (initially up to one hour) and/or the use of a vibrator as needed, and muscular control of sexual tension (alternating contraction and relaxation of the pelvic muscles during high sexual arousal). The latter is similar to Kegel exercises . Methods to minimize inhibition include distraction by “spectatoring” (observing oneself from a third-party perspective), fantasizing or listening to music. Women who do not respond to therapy should be referred to an appropriate therapist.
Kegel Exercises
Potential uses
|
Increased pubococcygeal tone
|
Improved orgasmic intensity
|
Correction of orgasmic urine leakage
|
Distraction technique during intercourse
|
Improved patient awareness of sexual response
|
Teaching Kegel exercises
|
Instructional examination with examiner's finger in vagina
|
Initial patient home exercise with patient's finger in vagina
|
Slow count to 10, with movement directed “in and up”
|
Hold for count of 3
|
Slow release to count of 10
|
Repeat 10 to 15 times daily
|
Consider vaginal weights, biofeedback clinics
|
Maintaining Kegel exercises
|
Advise repetitions during routine activities (standing in line, at stop lights, etc.)
|
Schedule follow-up appointments to discuss progress
|
SEX PAIN DISORDERS
Dyspareunia can be divided into three types of pain: superficial, vaginal and deep .
Superficial dyspareunia occurs with attempted penetration, usually
secondary to anatomic or irritative conditions, or vaginismus. Vaginal
dyspareunia is pain related to friction (i.e., lubrication problems),
including arousal disorders. Deep dyspareunia is pain related to
thrusting, often associated with pelvic disease or relaxation.Diagnosis of an underlying etiology should be aggressively sought, even if surgical investigation (laparoscopy) is required. The physical examination must include meticulous detail, with the physician's focus on recreating the pain. Treatment of the underlying etiology is fundamental, but as in long-term pain disorders, counseling and pain control strategies are essential. General recommendations for improved sexual function are discussed in and are similar despite sexual orientation.
Vaginismus, the involuntary contraction of the muscles of the outer one third of the vagina, is often related to sexual phobias or past abuse or trauma. Vaginismus may be complete or situational, so that a pelvic examination might be possible while intercourse is not. Therapy for and counseling of women with vaginismus can be initiated and often successfully completed by primary care physicians.
Treatment of women with vaginismus consists of progressive muscle relaxation and vaginal dilatation (actually a misnomer because the vagina is not physically stretched). Progressive muscle relaxation can be taught during an instructional examination by having the patient alternate contracting and relaxing the pelvic muscles around the examiner's finger. Women with vaginismus can achieve vaginal dilatation with the use of commercial dilators or tampons of increasing diameter, placed into the vagina for 15 minutes twice daily. Once the patient can easily accept an equivalent-sized dilator into the vagina, penile penetration by the partner can occur. Success rates approach 90 percent. Patients who do not respond to this therapy should be referred to a sex therapist who specializes in the treatment of women with this disorder .
Female Sexual Dysfunction: When to Refer
Longstanding dysfunction
|
Multiple dysfunctions
|
Current or past abuse
|
Psychologic disorder or acute psychologic event Unknown etiology
|
No response to therapy
|
No comments:
Post a Comment